EL7.AI
StocksMediumUpdated×3•Originally published 12 August 2026•Updated 13 August 2026•
1 min read

Liquidia Reports Strong Q2 2026 Profitability Driven by YUTREPIA Sales

Key Facts

1Liquidia Corporation achieved YUTREPIA net product sales of $170.4 million in Q2 2026, up 31% from the first quarter.
2The company recorded net income of $74.7 million, marking its fourth consecutive quarter of increasing profitability.

Reflecting a significant milestone in the biopharmaceutical sector, Liquidia Corporation reported robust financial results for the second quarter of 2026. According to reports, the company achieved net product sales of $170.4 million for YUTREPIA, a 31% sequential increase, and recorded a net income of $74.7 million. This performance marks the fourth consecutive quarter of profitability growth, driven by approximately 5,900 unique patient prescriptions since its June 2025 commercial launch.

Detailed financial metrics reveal high operational efficiency, with YUTREPIA's gross margin reaching approximately 93.7% and the company's overall operating margin hitting 49.8%. This growth occurred alongside strategic investments, including $17.2 million in R&D and $57.4 million in SG&A expenses. The company strengthened its liquidity position to $284.2 million in cash and equivalents as of June 30, 2026.

Looking ahead, Liquidia must generate approximately $210 million in quarterly revenue during Q3 and Q4 to meet the full-year 2026 consensus target of $725 million. Market participants are also monitoring the U.S. Initial Jobless Claims scheduled for August 6, 2026, for broader sentiment cues.